Search ARM

ARM Events

Jump To:

Cell & Gene Therapies State of the Industry Briefing

Back to ARM Events

Cell & Gene Therapies State of the Industry Briefing

Webcast & Industry Update PPT Now Available!

Couldn’t attend this year’s Cell & Gene Therapies State of the Industry Briefing in-person or looking to have a copy of the slides to reference again? View the full webcast below and download the 2018 Industry Update PPT presentation.

To see all three of the video options click on the horizontal bars in the upper left corner.

Download Presentation

2018 Program Agenda

 

8:00am – 8:20am | Introduction & Industry Update

Janet Lynch Lambert, CEO, Alliance for Regenerative Medicine
Robert Preti, Chairman, Alliance for Regenerative Medicine; President and CEO, Hitachi Chemical Advanced Therapeutics Solutions; GM, Hitachi Chemical Regenerative Medicine Business Sector

 

8:20am – 9:05am | Next Generation CARs and Other Cell-based Immunotherapies

Robert Preti, Chairman, Alliance for Regenerative Medicine; President and CEO, Hitachi Chemical Advanced Therapeutics Solutions; GM, Hitachi Chemical Regenerative Medicine Business Sector (chair)
Bob Azelby, EVP, Chief Commercial Officer, Juno Therapeutics
Manuel Litchman, President, CEO and Director, Mustang Bio
James Noble, CEO, Adaptimmune
Pascal Touchon, SVP and Global Head, Cell and Gene, Novartis Oncology
Scott Wolchko, President and CEO, Fate Therapeutics

 

9:05am – 9:50am | Gene Therapy: The Outlook in 2018

Martha Rook, Head of Gene Editing and Novel Modalities, MilliporeSigma (chair)
Bill Lundberg, CSO, CRISPR Therapeutics
Sandy Macrae, President and CEO, Sangamo Therapeutics
Geoff Nichol, SVP, Global Clinical Development and CMO, BioMarin Pharmaceutical
Amber Salzman, President and CEO, Adverum Biotechnologies
Deepak Srivastava, President, Gladstone Institutes; Professor, UC San Francisco

9:50am | Program Close

End of program.

 

 

Date:
January 7, 2019

Location:
Parc 55 San Francisco, A Hilton Hotel

55 Cyril Magnin St.
San Francisco, CA 94102

Who Attends?

Over 500 of the cell and gene therapy field’s top stakeholders including company founders, C-level business executives, investors, media, patient advocates and academic leaders interested in learning more on the sector’s recent advances and outlook for the industry in the coming year.

 

Held in Conjunction With:

 

Questions?
Please contact Laura Parsons at lparsons@alliancerm.org.